EG00229 is primarily utilized in research settings as a potent and selective agonist for the GPR55 receptor. Its application is significant in studying the physiological and pathological roles of GPR55 in various biological processes, including inflammation, pain modulation, and cancer. Researchers employ EG00229 to explore its potential therapeutic effects in conditions such as neuropathic pain, osteoporosis, and certain types of cancers where GPR55 signaling is implicated. Additionally, it serves as a valuable tool in understanding the endocannabinoid system and its interactions with other signaling pathways.